Marisa Suppatkul
Psychiatry · Houston, TXNPI 1306964739
Payments from drug & device makers
Across 466 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$857
- Johnson & Johnson$786
- Corium, LLC$653
- Supernus Pharmaceuticals, Inc.$578
- plus $4K from 23 others
What the payments were for
- Food & beverage$9,41099%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $1,363 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $1,014 |
| Otsuka America Pharmaceutical, Inc. | 43 | $857 |
| Johnson & Johnson | 26 | $786 |
| Corium, LLC | 26 | $653 |
| Supernus Pharmaceuticals, Inc. | 51 | $578 |
| Axsome Therapeutics, Inc. | 16 | $577 |
| Bausch Health US, LLC | 25 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $370 |
| Lundbeck LLC | 15 | $333 |
| Neurocrine Biosciences, Inc. | 10 | $326 |
| Tris Pharma Inc | 16 | $318 |
| Vanda Pharmaceuticals Inc. | 10 | $244 |
| Idorsia Pharmaceuticals US Inc | 8 | $232 |
| Sunovion Pharmaceuticals Inc. | 15 | $211 |
| Ironshore Pharmaceuticals Inc. | 10 | $181 |
| Noven Therapeutics, LLC | 8 | $147 |
| E.r. Squibb & Sons, L.L.C. | 5 | $142 |
| Neos Therapeutics, LP | 4 | $130 |
| Alkermes, Inc. | 5 | $124 |
| Teva Pharmaceuticals USA, Inc. | 6 | $118 |
| Avanir Pharmaceuticals, Inc. | 4 | $63 |
| Shire North American Group Inc | 3 | $53 |
| OWP Pharmaceuticals, Inc. | 2 | $46 |
| Eisai Inc. | 2 | $42 |
| Alfasigma USA, Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Indivior Inc. | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,483 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 19 | $2,741 |
| Bupropion XlBupropion Hcl | 17 | $891 |
| Duloxetine Hcl | 23 | $684 |
| Lamotrigine | 13 | $335 |
| Trazodone Hcl | 20 | $120 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.